RxDoctor Payments Data

Juan Villamizar-Zuniga, MD

Family Medicine · Chicago, ILNPI 1326133711

Payments from drug & device makers

$986in general payments, 2019–2025

Across 18 payments — averaging $54.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boehringer Ingelheim$241
  • Lilly USA, LLC$165
  • AbbVie$156
  • AstraZeneca$138
  • Amarin Pharma, Inc.$75
  • Novo Nordisk$75
  • plus $137 from 2 others

What the payments were for

  • Food & beverage$95497%
  • Education$323%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boehringer Ingelheim3$241
Lilly USA, LLC3$165
AbbVie(2 entities)3$156
AstraZeneca2$138
Amarin Pharma, Inc.1$75
Novo Nordisk2$75
Merck1$69
GSK3$68

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$986 in reported general payments places this provider in the 70th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$2,088
Medicare patients
13
Services billed
20

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin147$145,247
OzempicSemaglutide41$45,097
FarxigaDapagliflozin Propanediol33$36,085
TrulicityDulaglutide32$33,396
LinzessLinaclotide17$18,112
EliquisApixaban15$15,188
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$5,040
Advair HfaFluticasone Propion/Salmeterol13$3,591
Humalog Kwikpen U-100Insulin Lispro11$1,941
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$1,612
Atorvastatin Calcium209$1,564
Albuterol Sulfate HfaAlbuterol Sulfate36$1,545
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$1,394
Alcohol PadsAlcohol Antiseptic Pads30$1,361
Nano 2nd Gen Pen NeedlePen Needle, Diabetic11$940

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$241$145,247147 claims
Novo NordiskOzempic$75$45,09741 claims
AstraZenecaFarxiga$138$36,08533 claims
Lilly USA, LLCTrulicity$165$33,39632 claims
AbbVieLinzess$156$18,11217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →